PT  - JOURNAL ARTICLE
AU  - Benjamin Heyman
AU  - Yiping Yang
TI  - New developments in immunotherapy for lymphoma
AID  - 10.20892/j.issn.2095-3941.2018.0037
DP  - 2018 Aug 01
TA  - Cancer Biology and Medicine
PG  - 189--209
VI  - 15
IP  - 3
4099  - http://www.cancerbiomed.org/content/15/3/189.short
4100  - http://www.cancerbiomed.org/content/15/3/189.full
SO  - Cancer Biol Med2018 Aug 01; 15
AB  - The development of immunotherapies for lymphoma has undergone a revolutionary evolution over the past decades. Since the advent of rituximab as the first successful immunotherapy for B-cell non-Hodgkin lymphoma over two decades ago, a plethora of new immunotherapeutic approaches to treat lymphoma has ensued. Four of the most exciting classes of immunotherapies include: chimeric antigen receptor T-cells, bispecific antibodies, immune checkpoint inhibitors, and vaccines. However, with addition of these novel therapies the appropriate timing of treatment, optimal patient population, duration of therapy, toxicity, and cost must be considered. In this review, we describe the most-promising immunotherapeutic approaches for the treatment of lymphoma in clinical development, specifically focusing on clinical trials performed to date and strategies for improvement.